BioMarker Strategies

BioMarker Strategies is a tissue-based cancer diagnostics company developing a novel biomarker testing system to improve the treatment of cancer. The SnapPath^TM biomarker testing system, which is supported with $2.3m in SBIR funding from the National Cancer Institute, incorporates an automated, live tumor cell-processing device with first-in-class, functional, ex vivo biomarker tests to improve drug development and inform clinical decision making for targeted cancer therapeutics. SnapPath^TM is being developed to stimulate a patient's live tumor cells after biopsy to obtain a Functional Signaling Profile (FSP) of the signal transduction network that is not possible using current tumor processing methods and static biomarkers from dead, fixed tissue. SnapPath^TM will enable personalized medicine for cancer patients with breast, lung, pancreatic, melanoma, colon and other solid-tumors. The company was named one of the "Top 20 Most Promising Startups in the U.S." in 2010 by the Thomson-Reuters Venture Capital Journal.